Findings from a study published online in The Journal of the American Medical Association suggest that, compared to clinically guided dosing, genotype-guided warfarin dosing may reduce the risk of adverse events for joint arthroplasty patients. 

The authors conducted a multicenter, randomized, clinical trial of 1,597 patients aged 65 years or older who underwent hip or knee arthroplasty, and of whom 808 were assigned to genotype-guided warfarin dosing. They found that adverse events (major bleeding, international normalized ratio of 4 or greater, or venous thromboembolism) occurred in 87 patients (10.8 percent) in the genotype-guided group and 116 patients (14.7 percent) in the clinically guided warfarin dosing group. There were no deaths in either cohort. Learn more...

Comments (0)

There are no comments posted here yet

Submit Community Content

If you have orthopedic information that you would like to share with the Orthogate Community, please register/login and submit your news, event, job, article, case or workshop from the Submit Content menu under the My Account area. Learn more!